These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 23843632

  • 1. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinib.
    Tang SC, de Vries N, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    J Pharmacol Exp Ther; 2013 Sep; 346(3):486-94. PubMed ID: 23843632
    [Abstract] [Full Text] [Related]

  • 2. Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier.
    Poller B, Wagenaar E, Tang SC, Schinkel AH.
    Mol Pharm; 2011 Apr 04; 8(2):571-82. PubMed ID: 21309545
    [Abstract] [Full Text] [Related]

  • 3. Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment.
    Lagas JS, van Waterschoot RA, van Tilburg VA, Hillebrand MJ, Lankheet N, Rosing H, Beijnen JH, Schinkel AH.
    Clin Cancer Res; 2009 Apr 01; 15(7):2344-51. PubMed ID: 19276246
    [Abstract] [Full Text] [Related]

  • 4. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.
    Tang SC, Lagas JS, Lankheet NA, Poller B, Hillebrand MJ, Rosing H, Beijnen JH, Schinkel AH.
    Int J Cancer; 2012 Jan 01; 130(1):223-33. PubMed ID: 21351087
    [Abstract] [Full Text] [Related]

  • 5. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
    Tang SC, Nguyen LN, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Int J Cancer; 2014 Mar 15; 134(6):1484-94. PubMed ID: 24037730
    [Abstract] [Full Text] [Related]

  • 6. P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib.
    Tang SC, Lankheet NA, Poller B, Wagenaar E, Beijnen JH, Schinkel AH.
    J Pharmacol Exp Ther; 2012 Apr 15; 341(1):164-73. PubMed ID: 22238213
    [Abstract] [Full Text] [Related]

  • 7. Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
    Durmus S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Mol Pharm; 2012 Nov 05; 9(11):3236-45. PubMed ID: 23020847
    [Abstract] [Full Text] [Related]

  • 8. Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics.
    Poller B, Iusuf D, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Drug Metab Dispos; 2011 May 05; 39(5):729-35. PubMed ID: 21282407
    [Abstract] [Full Text] [Related]

  • 9. Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2).
    Kort A, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Pharmacol Res; 2015 Dec 05; 102():200-7. PubMed ID: 26361725
    [Abstract] [Full Text] [Related]

  • 10. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.
    Durmus S, Xu N, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Pharmacol Res; 2013 Oct 05; 76():9-16. PubMed ID: 23827160
    [Abstract] [Full Text] [Related]

  • 11. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib.
    Chen Y, Agarwal S, Shaik NM, Chen C, Yang Z, Elmquist WF.
    J Pharmacol Exp Ther; 2009 Sep 05; 330(3):956-63. PubMed ID: 19491323
    [Abstract] [Full Text] [Related]

  • 12. Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics.
    Mizuno T, Fukudo M, Terada T, Kamba T, Nakamura E, Ogawa O, Inui K, Katsura T.
    Drug Metab Pharmacokinet; 2012 Sep 05; 27(6):631-9. PubMed ID: 22673043
    [Abstract] [Full Text] [Related]

  • 13. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters.
    Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, Sparreboom A, Baker SD.
    Clin Cancer Res; 2009 Oct 01; 15(19):6062-9. PubMed ID: 19773380
    [Abstract] [Full Text] [Related]

  • 14. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation.
    van Hoppe S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Pharmacol Res; 2017 Jun 01; 120():43-50. PubMed ID: 28288939
    [Abstract] [Full Text] [Related]

  • 15. P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability.
    Li W, Sparidans RW, Wang Y, Lebre MC, Beijnen JH, Schinkel AH.
    Pharmacol Res; 2018 Nov 01; 137():47-55. PubMed ID: 30253203
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1).
    Kort A, Durmus S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Pharm Res; 2015 Jul 01; 32(7):2205-16. PubMed ID: 25563977
    [Abstract] [Full Text] [Related]

  • 18. Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study.
    Tandia M, Mhiri A, Paule B, Saffroy R, Cailliez V, Noé G, Farinotti R, Bonhomme-Faivre L.
    Cancer Chemother Pharmacol; 2017 Apr 01; 79(4):759-766. PubMed ID: 28289864
    [Abstract] [Full Text] [Related]

  • 19. Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors.
    Dudek AZ, Raza A, Chi M, Singhal M, Oberoi R, Mittapalli RK, Agarwal S, Elmquist WF.
    Clin Genitourin Cancer; 2013 Jun 01; 11(2):155-60. PubMed ID: 23265925
    [Abstract] [Full Text] [Related]

  • 20. P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice.
    Wang J, Gan C, Retmana IA, Sparidans RW, Li W, Lebre MC, Beijnen JH, Schinkel AH.
    Int J Pharm; 2019 Feb 10; 556():172-180. PubMed ID: 30553002
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.